Prostate-Specific Antigen Free Absolute
PSA F ABS
Description
"Prostate-Specific Antigen (PSA) Free Absolute" test measures the amount of unbound PSA circulating in your blood. This test is used alongside total PSA to refine prostate cancer risk assessment and evaluate conditions like prostatitis or benign prostatic hyperplasia. Low free PSA levels may signal a higher likelihood of cancer. Doctors often recommend this test when total PSA is elevated or symptoms like urinary difficulty are present. Results help determine if further testing, such as a biopsy, is necessary.
Category
Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
Nanograms Per Milliliter
Procedure Category
Blood Draw
Test Group
Male Hormone Group, Complete Prostate Group
Test Group Description
Complete Prostate Group: Extensive tests offering a comprehensive assessment of prostate health, providing detailed insights into prostate function and associated conditions. Male Hormone Group: It focuses on assessing hormone levels specific to male health, providing insights into reproductive function and hormonal balance.
Optimal Range
For All Individuals:
Conventional Unit: 0.00–2.00 ng/mL
SI Unit: Not Available
Normal Range
For All Individuals:
Conventional Unit: 0.00–4.00 ng/mL
SI Unit: Not Available
Results That Differ From The Norm (Direct and Indirect Causes)
Abnormal results may indicate:
Aging
Benign prostatic hyperplasia (Non-cancerous enlargement of the prostate gland)
Medications (such as 5-alpha reductase inhibitors)
Prostate biopsy (Procedure involving the removal of prostate tissue)
Prostate cancer (Malignant growth of cells in the prostate gland)
Prostatitis (Inflammation of the prostate gland)
Recent prostate surgery
Supplements (such as 5-alpha-reductase inhibitors)
Urinary tract infections
Key Reasons For Testing
Prostate Cancer Screening: Provides additional information alongside total PSA to assess prostate cancer risk.
Differentiating BPH from Prostate Cancer: Helps distinguish between benign prostatic hyperplasia and prostate cancer, as free PSA levels tend to be lower in prostate cancer.
Monitoring Prostate Cancer Treatment: Tracks PSA-free levels to evaluate response to treatments like surgery or hormone therapy.
Assessment of Recurrence: Detects early signs of prostate cancer recurrence after initial treatment.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547.
[2] Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-1455.
[3] Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;50(6):1017-1025.
[4] Vickers AJ, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer.2010;116(11):2612-2620.
[5] Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
[6] Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163-1169.
[7] Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1193-1200.
[8] Stephan C, Jung K, Cammann H, et al. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Biomark. 2010;6(4):193-201.
[9] Filella X, Foj L. Prostate cancer detection and prognosis: from prostate-specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17(11):1784.
[10] Haese A, Graefen M, Noldus J, et al. Prostate-specific antigen progression in untreated patients with prostate cancer and initial PSA level below 10 ng/mL. Eur Urol. 2003;43(2):124-129.
[11] Vickers AJ, Cronin AM, Roobol MJ, et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16(17):4374-4381.
[12] Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection, and monitoring. Nat Rev Cancer. 2008;8(4):268-278.